tirzepatide oral tablets vs injection Pills: Formulation Basics, Bioavailability Tirzepatide Tablets: Safety, Risks &

You can switch providers at any point during treatment

Ruhoys Take: Could GLP-1 Medications Help MCAS & Fatigue

Sinno, H

Heres why this move deserves attention Big Bet on a Blockbuster Segment Entry into the fast-growing GLP-1 (semaglutide) space Taps into a market set to explode with rising diabetes & obesity cases Timed perfectly post patent expiry early-mover advantage Product That Matches Global Standards Once-weekly injectable better patient adherence Available in 2 mg & 4 mg pre-filled pens Backed by Phase III data comparable efficacy + strong safety Premium Generic Strategy (Not a Price WarYet) Priced at ~4,200/month Positioned as a trusted, high-quality branded generic Targets urban, quality-conscious patients over deep discounting Full-Stack Manufacturing Power API + formulation + delivery device all in-house Strong edge in complex peptides & scale-up capability Sets the stage for global expansion Beyond Drug: Building a Patient Ecosystem SemaKare support program Focus on adherence, education & outcomes Shift from product-selling solution-building Competitive Storm Incoming Multiple Indian pharma giants entering semaglutide Likely outcomes: Price erosion Wider access Massive market expansion The Real Play

Injection site reactions(redness or discomfort) No major adverse reactions have been reported in studies, but more research is needed to fully understand its safety profile

They could do so at a significant discount because vials are cheaper to produce than the branded injectables, making them a popular option for cash-paying patients